U.S. flag An official website of the United States government
  1. Home
  2. Drug Databases
  3. Drug Shortages

FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Report a Drug Shortage | FAQ | Background Info | Get Email Alerts | Download Current Drug Shortages | Contact Us

Start Over | Back to Previous Screen

Methylphenidate Hydrochloride Tablet, Extended Release
Status: Currently in Shortage
»Date first posted: 07/26/2023
»Therapeutic Categories: Psychiatry

Expand all

Dr. Reddy's Laboratories, Inc. (Reverified 11/19/2024)

Company Contact Information:
866-732-3952

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Tablet, Extended Release, 18 mg (NDC 43598-438-01) Unavailable Estimated availability TBD Other
Tablet, Extended Release, 27 mg (NDC 43598-439-01) Unavailable Estimated availability TBD Other
Tablet, Extended Release, 36 mg (NDC 43598-440-01) Unavailable Estimated availability TBD Other
Tablet, Extended Release, 54 mg (NDC 43598-441-01) Unavailable Estimated availability TBD Other

Janssen Pharmaceuticals (Reverified 12/09/2024)

Company Contact Information:
800-JANSSEN (1-800-526-7736) Monday through Friday from 9:00 AM to 8:00 PM ET

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Concerta, Tablet, Extended Release, 18 mg (NDC 50458-585-01) Available
Concerta, Tablet, Extended Release, 27 mg (NDC 50458-588-01) Available
Concerta, Tablet, Extended Release, 36 mg (NDC 50458-586-01) Available
Concerta, Tablet, Extended Release, 54 mg (NDC 50458-587-01) Available

Lannett Company, Inc. (Reverified 12/02/2024)

Company Contact Information:
844-834-0530

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Tablet, Extended Release, 18 mg (NDC 62175-310-37) Limited Availability Shortage of an active ingredient
Tablet, Extended Release, 27 mg (NDC 62175-311-37) Limited Availability Shortage of an active ingredient
Tablet, Extended Release, 36 mg (NDC 62175-312-37) Limited Availability Shortage of an active ingredient
Tablet, Extended Release, 54 mg (NDC 62175-313-37) Available

SpecGx LLC (Revised 11/01/2024)

Company Contact Information:
800-325-8888

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Methylin Er, Tablet, Extended Release, 10 mg (NDC 0406-1445-01) Limited Availability Allocations to all customers. Backorder projected in October Shortage of an active ingredient
Methylin Er, Tablet, Extended Release, 20 mg (NDC 0406-1473-01) Limited Availability Allocation to all customers; Backorder projected in Jan. Shortage of an active ingredient
Tablet, Extended Release, 27 mg (NDC 0406-0127-01) Unavailable Backorder, next release expected early Dec. Backorder projected in January. Shortage of an active ingredient
Tablet, Extended Release, 36 mg (NDC 0406-0136-01) Unavailable Backorder with next release in Nov. Backorder projected in January. Shortage of an active ingredient
Tablet, Extended Release, 54 mg (NDC 0406-0154-01) Limited Availability Allocations to all customers. Backorder projected in January. Shortage of an active ingredient

Sun Pharmaceutical Industries, Inc. (Reverified 10/23/2024)

Company Contact Information:
800-818-4555

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 57664-606-88) Unavailable Shortage of an active ingredient
Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 57664-607-88) Unavailable Shortage of an active ingredient
Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 57664-608-88) Unavailable Currently Not Marketed Discontinuation of the manufacture of the drug
Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 57664-609-88) Unavailable Currently Not Marketed Discontinuation of the manufacture of the drug

Teva Pharmaceuticals USA, Inc. (Revised 12/06/2024)

Company Contact Information:
800-545-8800

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Methylphenidate Hydrochloride Extended-Release Tablets, USP CII, Tablet, Extended Release, 18 mg (NDC 62037-725-01) Limited Availability Recovery: December 2024 Demand increase for the drug
Methylphenidate Hydrochloride Extended-Release Tablets, USP CII, Tablet, Extended Release, 27 mg (NDC 62037-734-01) Available
Methylphenidate Hydrochloride Extended-Release Tablets, USP CII, Tablet, Extended Release, 36 mg (NDC 62037-726-01) Available
Methylphenidate Hydrochloride Extended-Release Tablets, USP CII, Tablet, Extended Release, 54 mg (NDC 62037-727-01) Limited Availability Recovery: December 2024 Demand increase for the drug

Trigen Laboratories, LLC (Revised 03/07/2024)

Company Contact Information:
800-541-4802

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Methylphenidate Hydrochloride, Tablet, Extended Release, 18 mg (NDC 13811-706-10) Available Allocation to current contracted customers Demand increase for the drug
Methylphenidate Hydrochloride, Tablet, Extended Release, 27 mg (NDC 13811-707-10) Available Allocation to current contracted customers Demand increase for the drug
Methylphenidate Hydrochloride, Tablet, Extended Release, 36 mg (NDC 13811-708-10) Available Allocation to current contracted customers Demand increase for the drug
Methylphenidate Hydrochloride, Tablet, Extended Release, 45 mg (NDC 13811-711-30) Available
Methylphenidate Hydrochloride, Tablet, Extended Release, 54 mg (NDC 13811-709-10) Available Allocation to current contracted customers Demand increase for the drug
Methylphenidate Hydrochloride, Tablet, Extended Release, 63 mg (NDC 13811-700-30) Available
Methylphenidate Hydrochloride, Tablet, Extended Release, 72 mg (NDC 13811-710-30) Available

Vertical Pharmaceuticals, LLC (Reverified 12/04/2024)

Company Contact Information:
800-541-4802

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-10) Available
Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-10) Available
Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-10) Available
Relexxii, Tablet, Extended Release, 45 mg (NDC 68025-088-30) Available
Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-10) Available
Relexxii, Tablet, Extended Release, 63 mg (NDC 68025-089-30) Available
Relexxii, Tablet, Extended Release, 72 mg (NDC 68025-084-30) Available
Relexxii, Tablet, Extended Release, 18 mg (NDC 68025-095-30) Available
Relexxii, Tablet, Extended Release, 27 mg (NDC 68025-096-30) Available
Relexxii, Tablet, Extended Release, 36 mg (NDC 68025-097-30) Available
Relexxii, Tablet, Extended Release, 54 mg (NDC 68025-098-30) Available
Back to Top